← Back to Search

Other

DC-806 for Plaque Psoriasis (Illuminate Trial)

Phase 2
Waitlist Available
Research Sponsored by DICE Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing a new oral medication called DC-806. It targets people with moderate to severe plaque psoriasis. The study will check how well the medication works, its safety, and how the body processes it.

Who is the study for?
Adults aged 18-70 with moderate to severe plaque psoriasis, who have had it for at least 6 months and are candidates for phototherapy or systemic therapy. They must have a BMI of 18-40 kg/m2 and agree to use effective contraception. Exclusions include certain abnormal lab values, recent flares or infections, history of significant mental health issues, strong drug interactions, heart abnormalities, chronic infections like HIV/hepatitis/TB, cancer in the last 5 years (except some skin cancers), or no response to specific psoriasis treatments.
What is being tested?
The trial is testing DC-806's effectiveness and safety compared to a placebo over a period of 12 weeks. Participants will be randomly assigned to receive either multiple oral doses of DC-806 or a placebo in double-blind fashion (neither participants nor researchers know who receives which treatment). The study also looks into how the body processes the drug.
What are the potential side effects?
While not specified here, common side effects for new psoriasis medications can include symptoms like nausea, diarrhea, headache, fatigue and potential risks for infection due to immune system impact. Specific side effects related to DC-806 would be detailed based on previous research phases.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment Group 4: DC-806 Dose DExperimental Treatment1 Intervention
Group II: Treatment Group 3: DC-806 Dose CExperimental Treatment1 Intervention
Group III: Treatment Group 2: DC-806 Dose BExperimental Treatment1 Intervention
Group IV: Treatment Group 1: DC-806 Dose AExperimental Treatment1 Intervention
Group V: Treatment Group 5: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DC-806
2023
Completed Phase 2
~300

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Plaque Psoriasis include TNF-alpha inhibitors, IL-12/23 inhibitors, and small molecules targeting specific pathways. TNF-alpha inhibitors reduce inflammation by blocking the tumor necrosis factor-alpha, a cytokine involved in systemic inflammation. IL-12/23 inhibitors target interleukins 12 and 23, which are crucial in the inflammatory process of psoriasis. Small molecules like DC-806, which are being studied, often inhibit specific enzymes or receptors involved in the pathogenesis of psoriasis, such as phosphodiesterase-4 (PDE4) inhibitors. These treatments are important for patients as they help reduce the chronic inflammation and abnormal skin cell growth characteristic of Plaque Psoriasis, leading to improved skin appearance and reduced symptoms.
Investigation on the Mechanism of Qubi Formula in Treating Psoriasis Based on Network Pharmacology.Trim21 promotes inflammation in keratinocytes of psoriatic patients.The Psoriasis Therapeutic Potential of a Novel Short Laminin Peptide C16.

Find a Location

Who is running the clinical trial?

DICE Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
41 Total Patients Enrolled
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyLead Sponsor
7 Previous Clinical Trials
448 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,369 Previous Clinical Trials
421,165 Total Patients Enrolled

Media Library

DC-806 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05896527 — Phase 2
Plaque Psoriasis Research Study Groups: Treatment Group 3: DC-806 Dose C, Treatment Group 5: Placebo, Treatment Group 1: DC-806 Dose A, Treatment Group 2: DC-806 Dose B, Treatment Group 4: DC-806 Dose D
Plaque Psoriasis Clinical Trial 2023: DC-806 Highlights & Side Effects. Trial Name: NCT05896527 — Phase 2
DC-806 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05896527 — Phase 2
Plaque Psoriasis Patient Testimony for trial: Trial Name: NCT05896527 — Phase 2
~98 spots leftby Oct 2025